506148 | InSolution™ p38 MAP Kinase Inhibitor III - Calbiochem

506148
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical Formula
      C₂₃H₂₁FN₄S

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      506148-1MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 1 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          Catalogue Number506148
          Brand Family Calbiochem®
          References
          ReferencesLaufer, S.A., et al. 2003. J. Med. Chem. 46, 3230.
          Product Information
          ATP CompetitiveY
          FormLiquid
          FormulationA 10 mM (1 mg/247 µl) solution of p38 MAP Kinase Inhibitor III (Cat. No. 506121) in DMSO.
          Hill FormulaC₂₃H₂₁FN₄S
          Chemical formulaC₂₃H₂₁FN₄S
          Hygroscopic Hygroscopic
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          ApplicationInSolution p38 MAP Kinase Inhibitor III, CAS 581098-48-8, is a 10 mM solution in DMSO. A cell-permeable, potent, selective, ATP-competitive p38 MAP kinase inhibitor (IC50 = 380 nM for p38α).
          Biological Information
          Primary Targetp38 MAP kinase
          Primary Target IC<sub>50</sub>0.38 µM for p38α; 0.16 and 0.039 µM in suppressing LPS-induced TNF-α and IL-1β release, respectively, in human PBMC; ED50 = 1.33 mg/kg in suppressing LPS-induced TNF-α release in mouse
          Purity≥98% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial use, aliquot and refrigerate (4°C).
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          506148

          References

          Reference overview
          Laufer, S.A., et al. 2003. J. Med. Chem. 46, 3230.

          Brochure

          Title
          Calbiochem Biologics 32.2
          In Solution!" Product Flyer
          MAPK Pathway Poster ( 750 KB )
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision15-August-2008 RFH
          DescriptionA cell-permeable, potent, selective, and ATP-competitive inhibitor of p38 MAP kinase (IC50 = 380 nM for p38α). Shown to effectively suppress LPS-induced cytokine release in vitro (IC50 = 160 nM for TNF-α release and 39 nM for IL-1β release, human PBMC) and in vivo (ED50 = 1.33 mg/kg for TNF-α release in mice). Exhibits reduced inhibitory activity against cytochrome P450-2D6 compared to SB 203580 (Cat. No 559389) and is better suited for use in animal models.
          FormLiquid
          FormulationA 10 mM (1 mg/247 µl) solution of p38 MAP Kinase Inhibitor III (Cat. No. 506121) in DMSO.
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₂₃H₂₁FN₄S
          Structure formulaStructure formula
          Purity≥98% by HPLC
          Storage +2°C to +8°C
          Hygroscopic
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial use, aliquot and refrigerate (4°C).
          Toxicity Standard Handling
          ReferencesLaufer, S.A., et al. 2003. J. Med. Chem. 46, 3230.